Aptar CSP Technologies has announced an expansion of its cGMP manufacturing capacity for clinical packaging of dry powder inhalation capsules using the company’s Activ-Blister technology. Aptar CSP cited growing demand for the technology for both oral dose and DPI capsules as the reason for launching the new site in New Jersey. According to the company, the site will offer services such as stability studies and clinical supply management in addition to manufacturing for Phase 1 and 2 clinical trials.
Aptar CSP Technologies VP Commercial Operations and General Manager Badre Hammond commented, “Launching this cGMP facility reinforces our commitment to delivering streamlined access to innovative active material science technologies for patients and pharmaceutical partners. By offering early-stage clinical services with custom-designed equipment, we simplify adoption, eliminate implementation barriers, and help avoid lengthy reformulation or repackaging efforts.”
Read the Aptar CSP press release
